Bessemer Group’s Cullinan Oncology CGEM Stock Holding History

Bessemer Group’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-436	Closed	-$3K	–	2507
2025 Q2	$3K	Buy	+436	New	+$3.5K	﹤0.01%	2117
2024 Q4	–	Sell	-105	Closed	-$2K	–	2486
2024 Q3	$2K	Buy	+105	New	+$1.86K	﹤0.01%	2174

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Bessemer Group's CGEM Position: Q3 2025 in Review

Bessemer Group sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 436 shares — an estimated $3K sold.

Bessemer Group first reported a position in CGEM in Q3 2024 and held it in 2 quarters. The position peaked at $3K in Q2 2025. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

Bessemer Group reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
Bessemer Group sold 436 Cullinan Oncology shares in Q3 2025, an estimated $3K.
Bessemer Group first reported a position in Cullinan Oncology in Q3 2024 and held it in 2 quarters.
Bessemer Group's Cullinan Oncology position peaked at $3K in Q2 2025.
145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.